BioRestorative Therapies
(NASDAQ) BRTX
BioRestorative Therapies Financials at a Glance
Market Cap
$9.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$357.87K
Net Income (TTM)
-$11.06M
EPS (TTM)
-$1.12
P/E Ratio
-0.33
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Price
$0.37
Volume
725
Open
$0.38
Price
$0.37
Volume
725
Open
$0.38
Previous Close
$0.37
Daily Range
$0.37 - $0.39
52-Week Range
$0.16 - $1.89
Estimated Earnings Date
Aug 11, 2026
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Price
$0.37
Volume
725
Open
$0.38
Previous Close
$0.37
Daily Range
$0.37 - $0.39
52-Week Range
$0.16 - $1.89
Estimated Earnings Date
Aug 11, 2026
BRTX News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout BioRestorative Therapies
Industry
Biotechnology
Sector
Health CareEmployees
14
CEO
Lance Alstodt
Website
www.biorestorative.comHeadquarters
Melville, NY 11747, US
BRTX Financials
Key Financial Metrics (TTM)
Gross Margin
92.09%
Operating Margin
-3975.00%
Net Income Margin
-3089.55%
Return on Equity
-423.84%
Return on Capital
-4386.10%
Return on Assets
-238.27%
Earnings Yield
-3.03%
Dividend Yield
0.00%
Payout Ratio
-0.05%
Stock Overview
Market Cap
$9.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
25.48M
Volume
725
Avg. Volume
10.52M
Financials (TTM)
Gross Profit
$329.55K
Operating Income
-$14.23M
EBITDA
-$10.85M
Operating Cash Flow
-$11.82M
Capital Expenditure
-$79.68K
Free Cash Flow
-$11.90M
Cash & ST Invst.
$3.59M
Total Debt
$34.52K
BioRestorative Therapies Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$23.17K
-7.3%
Gross Profit
$15.79K
-28.5%
Gross Margin
68.13%
N/A
Market Cap
$9.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$862.09K
N/A
Employees
11
N/A
Net Income
-$2.15M
+59.7%
EBITDA
-$2.10M
+60.2%
Quarterly Fundamentals
Total Cash
$3.59M
-60.6%
Total Debt
$34.52K
N/A
Accounts Receivable
$13.30K
-46.8%
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$34.52K
N/A
Return on Assets
-2.38%
N/A
Return on Invested Capital
-4.70%
N/A
Free Cash Flow
-$3.81M
-35.3%
Operating Cash Flow
-$3.81M
-37.0%